On being metachromatic: Mystique and misunderstanding in mastocytosis

American Journal of Hematology

Volumn 84, Issue 12, 2009, Pages 779-781

  Gotlib, Jason ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; CLADRIBINE; DASATINIB; HYDROXYUREA; IMATINIB; MIDOSTAURIN;

DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; MASTOCYTOSIS; MEDICAL EDUCATION; NOTE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; SYSTEMIC MASTOCYTOSIS;

CELL SHAPE; CLADRIBINE; CYTOPLASMIC GRANULES; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; STAINING AND LABELING;

EID: 73349096891     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21575     Document Type: Note

References (37)

1. Horny HP, Valent P. Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001;25:543-551.
2. Horny H-P, Metcalfe DD, Bennett JM, et al. Mastocytosis. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. pp 54-63.
3. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: A consenus proposal. Leuk Res 2001;25:603-625.
4. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001;25:519-528.
5. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: State of the art. Br J Haematol 2003;122:695-717.
6. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage disease: A histopathological challenge. J Clin Pathol 2004;57:604-608.
7. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations, and response criteria. Eur J Clin Invest 2007;37:435-453.
8. Lim K-H, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate, or 2-chlorodeoxyadenosine. Am J Hematol.
9. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low- dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003;348:994-1004.
10. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
11. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors New Engl J Med 2002; 347:472-480.
12. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-536.
13. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481-1484.
14. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22:660-664.
15. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686-692.
16. Ma Y, Zeng S, Metcalfe DD, et al. The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-1744.
17. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103:3222-3225.
18. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102:3093-3096.
19. Corless CL, Harrell PL, Lacouture M, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006;8:604-612.
20. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am 2006;26:575-592.
21. Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108:286-291.
22. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-481.
23. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005;106:721-724.
24. Gotlib J, Berubé C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005;106:2865-2870.
25. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008;14:3906-3915.
26. Gotlib J, George TI, Corless C, et al. The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial (Abstract). Blood 2007; 110:1035a.
27. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Blood 2006;107:752-759.
28. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood, in press.
29. Sotlar K, Bache A, Stellmacher F, et al. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: A distinct subtype of systemic mastocytosis associated with a clonal hematological non-mast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn 2008;10:58-66.
30. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372.
31. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001;344:307-309.
32. Kluin-Nelemans HC, Oldhoff JM, van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003;102:4270-4276.
33. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004;28:127-131.
34. Lortholary O, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 33 patients (Abstract). Blood 2004;104:190a.
35. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998;138:489-495.
36. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: Results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:1090-1097.
37. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res 2004;28:249-257.